Key terms
About EDIT
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EDIT news
Apr 22
4:55am ET
Editas Medicine management to meet with Oppenheimer
Apr 19
4:36pm ET
Editas Medicine management to meet with Oppenheimer
Mar 05
7:25am ET
Editas Medicine (EDIT) Receives a New Rating from a Top Analyst
Mar 01
1:17am ET
Strong Buy Rating for Editas Medicine: Promising Pipeline and Strategic IP Position Drive Optimism
Mar 01
1:06am ET
Editas Medicine: Balanced Prospects and a Hold Rating with Modest Price Target Increase
Feb 29
8:07am ET
Oppenheimer Sticks to Its Hold Rating for Editas Medicine (EDIT)
Feb 29
7:19am ET
RBC Capital Reaffirms Their Hold Rating on Editas Medicine (EDIT)
Feb 29
6:28am ET
Editas Medicine price target raised to $16 from $11 at Citi
Feb 29
5:45am ET
Editas Medicine price target raised to $11 from $10 at Barclays
Feb 29
5:43am ET
Hold Rating on Editas Medicine Pending Clinical Trial Outcomes and Market Differentiation Potential
Feb 29
5:41am ET
Buy Recommendation for Editas Medicine Backed by Strong SCD Treatment Outlook and Solid Financials
Feb 29
2:51am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Schrodinger (SDGR), Editas Medicine (EDIT) and MacroGenics (MGNX)
Feb 28
5:28pm ET
Editas Medicine files automatic mixed securities shelf
Feb 28
12:15pm ET
TD Cowen Sticks to Its Buy Rating for Editas Medicine (EDIT)
Feb 28
7:03am ET
Editas Medicine expects cash to fund operations into 2026
Feb 28
7:02am ET
Editas Medicine reports Q4 EPS (23c), consensus (54c)
No recent press releases are available for EDIT
EDIT Financials
Key terms
Ad Feedback
EDIT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EDIT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range